IBI346

DRUG2 trials

Sponsors

Chunrui Li, The First Affiliated Hospital of Soochow University

Conditions

Relapsed/Refractory Multiple Myeloma

Phase 1

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Chunrui LiRelapsed/Refractory Multiple Myeloma

Start: 2022-04-28End: 2024-02-28Target: 36Updated: 2022-11-30

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

CompletedNCT05270928

The First Affiliated Hospital of Soochow UniversityRelapsed/Refractory Multiple Myeloma

Start: 2022-04-27End: 2023-05-29Updated: 2023-07-27

Related Papers

P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES

HemaSphere2023-08-014 citations